Arcellx (ACLX) Gains from Sales and Divestitures (2025)
Arcellx (ACLX) recorded quarterly Gains from Sales and Divestitures of $810498.0 in Q4 2025, up 21.26% quarter-over-quarter from $668416.0 in Q3 2025.
Arcellx (ACLX) Gains from Sales and Divestitures (2025) Analysis & Trends
Arcellx's Gains from Sales and Divestitures history runs 1 years deep, the most recent figure standing at $810498.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $810498.0; the TTM figure through Dec 2025 stood at $810498.0 (changed N/A YoY), while the FY2025 annual figure was $810498.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $810498.0 for Q4 2025 at Arcellx, up from $668416.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $810498.0 in Q4 2025 to a low of $347255.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 810,498.00 |
| Dec 31, 2025 | 810,498.00 |
| Sep 30, 2025 | 668,416.00 |
| Sep 30, 2025 | 668,416.00 |
| Jun 30, 2025 | 347,255.00 |
| Jun 30, 2025 | 347,255.00 |
| Mar 31, 2025 | 347,255.00 |
| Mar 31, 2025 | 347,255.00 |